Pharmafile Logo

NICE

- PMLiVE

NICE recommends Roche’s Polivy for B-cell lymphoma

Cost-effectiveness agency approves drug following initial rejection earlier this year

Unleashing the Potential of Multichannel Digital Strategies in Healthcare

Christine Jacob, Founder and Managing Director of Digi-Bridges, talks about the future of mobile and digital health, including exciting technologies such as VR and AR. We also touch on a wide variety...

Impetus Digital

- PMLiVE

NICE recommends Astellas’ Xospata for NHS use

Cost-effectiveness watchdog backtracks on previous rejection

HOW INNOVATION IS RESHAPING THE NORTH EAST LIFE SCIENCES LANDSCAPE

The North East has a world leading reputation in fields of life science and pharmaceuticals; however, the sector's focus has shifted away from its manufacturing roots towards more innovation focused...

Onyx Health

Impetus Digital Fireside Chat With Richie Bavasso From NqMedical

Richie Bavasso, founder and CEO of nQMedical, discusses everything from digital therapeutics, diagnostics, and other data-driven solutions for neurodegenerative diseases to Richie’s favorite media outlets, his work at nQMedical, and lessons learned...

Impetus Digital

Onyx Health Wins New MedTech Client

Onyx Health have recently bagged a new business win with Cambridge based MedTech company Medovate to launch their pioneering medical device SAFIRA in the United States

Onyx Health

- PMLiVE

NICE looks internally for new chief executive

Deputy chief exec Gillian Leng is set to take the helm

- PMLiVE

Celgene’s Revlimid scores NICE approval in follicular lymphoma

New ‘chemotherapy-free’ treatment for patients with limited options

Digital Nation: How Australia became a digital health pioneer

Australia has adopted digital strategies to transform its healthcare system. We sat down with Rachel de Sain, who shares where, and how she contributed to improving digital health products and...

Blue Latitude Health

- PMLiVE

NICE plans to widen the net for data it uses in guidance

Plans to include electronic health records and real-world evidence

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

- PMLiVE

NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi

Initial guidance says drug is too costly but encourages further data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links